Fabrizio Calapai, Emanuela Esposito, Ilaria Ammendolia, Carmen Mannucci, Gioacchino Calapai, Mariaconcetta Currò, Luigi Cardia, Ioanna Chinou
Cannabidiol (CBD) is a multitarget agent possessing anti-inflammatory and antioxidant properties. Unlicensed CBD gained public favor for the care of general health and well-being as well as to get comfort from inflammatory complaints, pain, anxiety, mood, and sleep disorders. Safety profile of unlicensed CBD has been not sufficiently described. For this reason, suspected adverse reactions (SARs) to CBD unlicensed products were analyzed. Serious SARs to unlicensed CBD products in EudraVigilance, a system purchased by the European Medicines Agency, were analyzed for age, sex of the patient, adverse reactions, indication for use, and concomitant drugs...
October 6, 2023: Phytotherapy Research: PTR